Hyperglycemia associated with diabetes promotes a prothrombotic state by affecting a number of different steps in the clotting pathway. Which of the following would result inmore rather than less clotting? Check all that apply. The correct answers reflect the effect of hyperglycemia on the clotting pathway!less conversion of plasminogen to plasmin7000000000abnormally low number of plateletsplatelets more sensitive to thromboxane A2elevated conversion of plasminogen to plasminplatelets less sensitive to thromboxane A2low sensitivity to NO and PGI2increased prothrombin in the bloodincreased amount of fibrinogen in the bloodless prothrombin in the bloodabnormally high number of plateletsless fibrinogen in the bloodhigh sensitivity to NO and PGI2

Yes, increased blood component levels in diabetes result in rapid blood clotting. Diabetes-related…

Hyperglycemia associated with diabetes promotes a prothrombotic state by affecting a number of different steps in the clotting pathway. Which of the following would resul more rather than less clotting? Check all that apply. The correct answers reflect the effect of hyperglycemia on the clotting pathway! less conversion of plasminogen to plasmin abnormally low number of platelets platelets more sensitive to thromboxane A2 elevated conversion of plasminogen to plasmin platelets less sensitive to thromboxane A2 low sensitivity to NO and PGI2 increased prothrombin in the blood increased amount of fibrinogen in the blood less prothrombin in the blood abnormally high number of platelets less fibrinogen in the blood high sensitivity to NO and PGI2

Hyperglycemia associated with diabetes promotes a prothrombotic state by affecting a number of different steps in the clotting pathway. Which of the following would resul more rather than less clotting? Check all that apply. The correct answers reflect the effect of hyperglycemia on the clotting pathway! less conversion of plasminogen to plasmin abnormally low number of platelets platelets more sensitive to thromboxane A2 elevated conversion of plasminogen to plasmin platelets less sensitive to thromboxane A2 low sensitivity to NO and PGI2 increased prothrombin in the blood increased amount of fibrinogen in the blood less prothrombin in the blood abnormally high number of platelets less fibrinogen in the blood high sensitivity to NO and PGI2

Human Physiology: From Cells to Systems (MindTap Course List)

9th Edition

ISBN:9781285866932

Author:Lauralee Sherwood

Publisher:Lauralee Sherwood

Chapter11: The Blood

Section: Chapter Questions

Problem 3SQE

See similar textbooks

Similar questions

It is known that heparin acts by increasing the activity of antithrombin, causing a conformational change. LMWHs inhibit mainly factor Xa. Although low doses of heparin act primarily by neutralizing factor Xa, at high doses it prevents thrombin-induced platelet activation and prolongs bleeding time. What are major clinical benefits using heparin or LMWHs?
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions What is the advantage of measuring autophosphorylation of the receptor rather than phosphorylation of the substrate?
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions How would you apply a TR-FRET assay to measure the in vitro kinase activity of VEGFR-2? Describe in steps the assay design and potential readout outcome.
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions While setting up your experiment, you accidentally discovered autophophorylation of receptor. What observation/results led you to believe that there was autophosphorylation of the receptor?
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions How would you determine robustness of the assay and validate the assay?
Calculate the hematocrit of a female patient using the following information:The height of the whole body is 80mm, and the height of the RBC's is 28mm. How is her hematocrit value as compared to the hematocrit normal value of adult femal?
Vascular endothelial growth factor receptor 2 (VEGFR-2) is an endothelial cell-specific receptor that has inherent tyrosine kinase activity. The binding of the Vascular endothelial growth factor (VEGF) ligand to its receptor plays an important role in angiogenesis, a process by which new capillaries are formed. Enhanced angiogenesis is associated with a number of diseases including cancer. Your goal is to develop a homogeneous in vitro TR-FRET kinase assay for VEGFR-2 (purified protein) in an attempt to identify small molecules that inhibit kinase activity and in turn modulate angiogenesis. Based on this background, please answer the following questions If you wanted to measure the kinase activity of VEGFR-2, what are some of the conventional methods/assays you would use?
Select all the options below which are false of hemostasis. | aspirin is an effective "blood thinner" (anticoagulant) because it prevents the formation and release of ADP by platelet plugs | after damage to a vessel, the immediate reaction is vasodilation to bring more white blood cells in and prevent infection O factor X is the converging point of both the intrinsic and extrinsic pathways of the clotting cascade when platelets begin to aggregate, a negative feedback loop begins to cause more platelets to aggregate
Since in this patient, pyruvate kinase is abnormal not only is less pyruvate made but intermediates above pyruvate in the glycolytic pathway build up slowing the pathway. Question is, which of the following products may not be made in the appropriate amounts in the RBC because of the deficiency of pyruvate? Explain.
Heparin is an activator of antithrombin III. In addition to thrombin, which additional coagulation factors are targeted by the antithrombin IlI:heparin complex? Currently Selected : B A Factor X В Factor VII Factor VIII Factor V
Hypoxia is believed to turn on the ‘angiogenic switch’ in tumors. What role do each of the following play in either turning on or turning off the switch? How is the action of switching off inhibited in tumors? Macrophages, VEGF, MMPs, Tsp-1
Which of the following is not an extensive property The combination of equivalent amounts of acids and bases is called? What is the correct sequence of the different stages in blood clotting? I Fibrinogin thrombin fibrin/II Prothrombin thromboplastin Thrombin Ca